Adaptive biotechnologies stock.

The stock price of Adaptive Biotechnologies Corp (NASDAQ: ADPT) has jumped by 5.72 compared to previous close of 4.37. Despite this, the company has seen a gain of 9.48% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-09 that Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2023 Earnings Conference Call November […]52 Week Low. Data Provided by Refinitiv. Minimum 15 minutes delayed. RSS Feeds.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Adaptive Biotechnologies CEO on the company’s IPO and pipeline. Adaptive has agreed to spend a minimum of $12 million on Azure over seven years, according to its IPO prospectus, and Microsoft is ...

Earnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.35) to ($1.10) per share. Adaptive Biotechnologies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 13th, 2024 based off prior year's report dates. Read More.Adaptive Biotechnologies (NASDAQ: ADPT) $4.31 (6.9%) $0.28 Price as of November 17, 2023, 4:00 p.m. ET Overview Return vs. S&P News & Analysis Financial Health …

Jun 30, 2023 · Second Quarter 2023 Financial Results. Revenue was $48.9 million for the quarter ended June 30, 2023, representing a 12% increase from the second quarter in the prior year. Immune Medicine revenue was $23.0 million for the quarter, representing a 3% increase from the second quarter in the prior year.

Nov 29, 2023 · Get a real-time Adaptive Biotechnologies Corporation (ADPT) stock price quote with breaking news, financials, statistics, charts and more. ... The 12-month stock ... Samples were sent overnight at ambient temperature to Adaptive Biotechnologies (Seattle, WA) for processing. Plasma was isolated within 5 days of collection. ctDNA levels were subsequently determined from isolated plasma via next-generation sequence as described. 13 Clinicians did not have these data available at the …Get the latest Adaptive Biotechnologies Corp (ADPT) real-time quote, historical performance, charts, and other financial information to help you make more informed …About Adaptive Biotechnologies Stock. Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human …

In summary, Adaptive Biotechnologies Corp (ADPT) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

The latest Adaptive Biotechnologies Corporation Registered Shs stock prices, stock quotes, news, and ADPT history to help you invest and trade smarter.

Adaptive Biotechnologies announced its first quarter earnings Wednesday, ... Adaptive’s stock value at market close Wednesday was $9.25, down from its high in February 2021 of nearly $70.Mar 31, 2023 · Revenue was $37.6 million for the quarter ended March 31, 2023, representing a 3% decrease from the first quarter in the prior year. Immune Medicine revenue was $16.2 million for the quarter, representing a 22% decrease from the first quarter in the prior year mainly driven by a decline in amortization of the Genentech upfront payment. Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued. The Investor Relations website contains information about Adaptive Biotechnologies's business for stockholders, potential investors, and financial analysts.Adaptive Biotechnologies Corp is down 7.85% from its previous closing price of $5.22. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $5.12 and $5.30. Currently, there are 144.40 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive …Adaptive Biotechnologies Corporation will report financial results for Q3 2023 on November 9, 2023. The company aims to translate the genetics of t...

Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%.Dec 4, 2023 · The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is an Overweight stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021 ...Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating. Oct. 24. MT. BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating. Oct. 20. Dec 1, 2023 · A high-level overview of Adaptive Biotechnologies Corporation (ADPT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Meet Adaptive. The adaptive immune system is a force inside your body so powerful it’s able to detect disease and fight it, often before you even realize that you’re sick. Adaptive Biotechnologies is harnessing this vast system of biology to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine.

Adaptive Biotechnologies Corporation published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 10 January 2022 20:27:03 UTC .Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. Shares of ImmunoGen closed nearly 83% …May 3, 2023 · Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago. These ... SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth …In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070.00 in company stock. Percentage Held by Insiders. Only 5.20% of the stock of Adaptive Biotechnologies is held by insiders. Percentage Held by InstitutionsAdaptive Biotechnologies ( ADPT -9.24%) is a biotech-adjacent stock that peaked in January and then fell hard. It's down 61% from its high-water mark, but the average analyst on Wall Street thinks ...Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. …Jun 2, 2023 · SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ...

Meet Adaptive. The adaptive immune system is a force inside your body so powerful it’s able to detect disease and fight it, often before you even realize that you’re sick. Adaptive Biotechnologies is harnessing this vast system of biology to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine.

Nov 30, 2023

SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to …Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third ...Get the latest Adaptive Biotechnologies Corp (ADPT) real-time quote, historical performance, charts, and other financial information to help you make more informed …Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Interested individuals can access further details through the hyperlink provided by Adaptive Biotechnologies. Overall insider trading activity for Adaptive Biotechnologies has been noteworthy, with insiders recently selling 242,961 shares of the company’s stock. These transactions have amounted to a total value of $1,967,763.Bluebird Bio. Market Cap. $466M. Today's Change. (11.52%) $0.44. Current Price. $4.26. Price as of December 1, 2023, 4:00 p.m. ET. You’re reading a free …Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2021 and December 31, 2020; 140,663,755 and 137,646,896 shares issued and outstanding at June 30, 2021 and …Adaptive Biotechnologies Corp ADPT Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation...

In summary, Adaptive Biotechnologies Corp (ADPT) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual ... What percentage of Adaptive Biotechnologies stock is owned by insiders? 5.20% of Adaptive Biotechnologies stock is owned by insiders. Learn more on ADPT's insider holdings.Instagram:https://instagram. best free stock portfolio trackerconditional coverage life insurancehow much is a gold bar costfaststock Looking for the best gutter downspout adapters and components? We put together the top 8 models for your next gutter project. Expert Advice On Improving Your Home Videos Latest View All Guides Latest View All Radio Show Latest View All Podc...Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target best stocks below 20spy etf dividend Adaptive Biotechnologies Chief Scientific Officer Harlan Robins signs the final beam during a “topping off” ceremony at the company’s future headquarters on Thursday, 23, 2020 in Seattle ...Mar 31, 2023 · Revenue was $37.6 million for the quarter ended March 31, 2023, representing a 3% decrease from the first quarter in the prior year. Immune Medicine revenue was $16.2 million for the quarter, representing a 22% decrease from the first quarter in the prior year mainly driven by a decline in amortization of the Genentech upfront payment. mainstreet capital Complete Adaptive Biotechnologies Corp. stock information by Barron's. View real-time ADPT stock price and news, along with industry-best analysis. Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued.